And while we're on the subject, here's the latest example of bad news coming in great squawking flocks: AstraZeneca's Crestor is under suspicion, their new Exanta clotting drug is in major trouble, and now some terribly unimpressive clinical data comes out for Iressa in its ISEL trial.

Note that Tarceva, which I was blogging about a few days ago, would seem to have a big opportunity here. OSI's shareholders sure seem to think so. But I'm still not convinced that the two drugs are that different. We'll see as it goes into more general use. . .personally, if I were an OSI shareholder, I'd sell. Not the first time I've made the recommendation, come to think of it. . .

Update: Colby Cosh picks up on the "Black Friday" theme and adds some interesting comments on the terms under which Iressa came to the market in the first place.

(By the way, readers may have noticed I'm blogging this during the day today, which is a bit unusual. It's not going to be a regular feature, though - unfortunately for the blog and fortunately for me, the day job usually precludes it. But just for today, I feel like Glenn Reynolds. . .)